Theratechnologies (TSE:TH) had its price objective dropped by equities research analysts at National Bank Financial from C$11.25 to C$8.25 in a report issued on Friday, BayStreet.CA reports. The brokerage presently has a “sector perform” rating on the stock. National Bank Financial’s price objective points to a potential upside of 46.02% from the company’s previous close.
Other equities analysts have also recently issued reports about the stock. Stifel Nicolaus began coverage on shares of Theratechnologies in a research note on Tuesday, May 14th. They set a “buy” rating and a C$15.00 target price for the company. Royal Bank of Canada set a $184.00 target price on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, July 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of C$9.56.
Shares of Theratechnologies stock traded down C$0.54 on Friday, reaching C$5.65. The stock had a trading volume of 270,181 shares, compared to its average volume of 155,748. The business has a 50-day moving average price of C$6.75. The company has a current ratio of 2.46, a quick ratio of 1.97 and a debt-to-equity ratio of 145.32. Theratechnologies has a fifty-two week low of C$5.17 and a fifty-two week high of C$11.45. The company has a market capitalization of $503.71 million and a PE ratio of -115.10.
Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new position in Theratechnologies during the 1st quarter valued at $96,000. Mesirow Financial Investment Management Inc. acquired a new position in Theratechnologies during the 1st quarter valued at $328,000. LLBH Private Wealth Management LLC acquired a new position in Theratechnologies during the 1st quarter valued at $1,735,000. Finally, Monarch Partners Asset Management LLC acquired a new position in Theratechnologies during the 1st quarter valued at $4,256,000.
Theratechnologies Company Profile
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.